Art. -Nr.: HY-B0532

Trifluoperazine

10 Cited Publications

Kundenbewertung

Based on 10 publication(s) in Google Scholar

Trifluoperazine, an antipsychotic agent, acts by blocking central dopamine receptors. Trifluoperazine is a potent α1-adrenergic receptor antagonist. Trifluoperazine is a potent NUPR1 inhibitor exerting anticancer activity. Trifluoperazine is a calmodulin inhibitor, and also inhibits P-glycoprotein. Trifluoperazine can be used for the research of schizophrenia. Trifluoperazine acts as a reversible inhibitor of influenza virus morphogenesis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.87%
CAS. Nr.: 117-89-5
Formel: C₂₁H₂₄F₃N₃S
Molecular Weight:407.50

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Trifluoperazine Chemical Structure

CAS. Nr.: 117-89-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
Chemical Information
Publications (10)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Dopamine Receptor Isoform-spezifische Produkte anzeigen :

Alle Adrenergic Receptor Isoform-spezifische Produkte anzeigen :

Alle CaMK Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
KG-1a	IC₅₀	4.58 μM Compound: TFP	Antiproliferative activity against human KG1a cells assessed as reduction in cell viability incubated for 2 days by MTT assay Antiproliferative activity against human KG1a cells assessed as reduction in cell viability incubated for 2 days by MTT assay	[PMID: 31541872]
MCF7	IC₅₀	11.33 μM Compound: TFP	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 2 days by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 2 days by MTT assay	[PMID: 31541872]
MDA-MB-231	IC₅₀	21.58 μM Compound: TFP	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 2 days by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 2 days by MTT assay	[PMID: 31541872]
NCI-H1650	GI₅₀	12.2 μM Compound: Trifluoperazine	Cytotoxicity against human NCI-H1650 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human NCI-H1650 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26372073]
Neutrophil	IC₅₀	12.2 μM Compound: TFP	Antiinflammatory activity in fMLP/cytochalasin B stimulated rat neutrophils assessed as inhibition of beta-glucuronidase release preincubated for 10 mins measured 45 mins after fMLP/cytochalasin B challenge Antiinflammatory activity in fMLP/cytochalasin B stimulated rat neutrophils assessed as inhibition of beta-glucuronidase release preincubated for 10 mins measured 45 mins after fMLP/cytochalasin B challenge	[PMID: 12662101]
Neutrophil	IC₅₀	13.2 μM Compound: TFP	Antiinflammatory activity in fMLP/cytochalasin B stimulated rat neutrophils assessed as inhibition of lysozyme release preincubated for 10 mins measured 45 mins after fMLP/cytochalasin B challenge Antiinflammatory activity in fMLP/cytochalasin B stimulated rat neutrophils assessed as inhibition of lysozyme release preincubated for 10 mins measured 45 mins after fMLP/cytochalasin B challenge	[PMID: 12662101]
Neutrophil	IC₅₀	2.7 μM Compound: TFP	Inhibition of PMA-induced superoxide formation in Sprague-Dawley rat neutrophil Inhibition of PMA-induced superoxide formation in Sprague-Dawley rat neutrophil	[PMID: 16510283]
Neutrophil	IC₅₀	6.6 μM Compound: TFP	Inhibition of fMLP-induced superoxide formation in Sprague-Dawley rat neutrophil Inhibition of fMLP-induced superoxide formation in Sprague-Dawley rat neutrophil	[PMID: 16510283]
Neutrophil	IC₅₀	12.7 μM Compound: TFP	Inhibition of 5 ug/ml CB-stimulated Lysozyme release from rat neutrophils Inhibition of 5 ug/ml CB-stimulated Lysozyme release from rat neutrophils	[PMID: 17320246]
Neutrophil	IC₅₀	13.2 μM Compound: TFP	Inhibition of 1 uM fMLP-stimulated beta-Glucuronidase release from rat neutrophils Inhibition of 1 uM fMLP-stimulated beta-Glucuronidase release from rat neutrophils	[PMID: 17320246]
Neutrophil	IC₅₀	11.9 μM Compound: Trifluoperazine	Antiinflammatory activity against Sprague-Dawley rat neutrophils assessed as inhibition of fMLP/cytochalasin B-induced lysozyme release Antiinflammatory activity against Sprague-Dawley rat neutrophils assessed as inhibition of fMLP/cytochalasin B-induced lysozyme release	[PMID: 19699097]
Neutrophil	IC₅₀	12.5 μM Compound: Trifluoperazine	Antiinflammatory activity against Sprague-Dawley rat neutrophils assessed as inhibition of fMLP/cytochalasin B-induced beta-glucuronidase release Antiinflammatory activity against Sprague-Dawley rat neutrophils assessed as inhibition of fMLP/cytochalasin B-induced beta-glucuronidase release	[PMID: 19699097]
NIH-3T3-G185	IC₅₀	10.9 μM Compound: Trifluoperazine	TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	6.3 μM Compound: Trifluoperazine	TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	7.2 μM Compound: Trifluoperazine	TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NSC	IC₅₀	10.1 μM Compound: TFP	Cytotoxicity against human NSC cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human NSC cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29614416]
Sf9	IC₅₀	0.0005 M Compound: Trifluoperazine	Inhibition of protein kinase C(1:1mixture of PKC alpha & beta) expressed in Sf9 insect cells Inhibition of protein kinase C(1:1mixture of PKC alpha & beta) expressed in Sf9 insect cells	[PMID: 9873605]
Sf9	IC₅₀	0.5 mM Compound: Trifluoperazine	Inhibition of protein kinase C(1:1mixture of PKC alpha & beta) expressed in Sf9 insect cells Inhibition of protein kinase C(1:1mixture of PKC alpha & beta) expressed in Sf9 insect cells	[PMID: 9873605]
SK-BR-3	IC₅₀	15.89 μM Compound: TFP	Antiproliferative activity against human SKBR3 cells assessed as reduction in cell viability incubated for 2 days by MTT assay Antiproliferative activity against human SKBR3 cells assessed as reduction in cell viability incubated for 2 days by MTT assay	[PMID: 31541872]
SUM-159-PT	IC₅₀	17.03 μM Compound: TFP	Antiproliferative activity against human SUM159 cells assessed as reduction in cell viability incubated for 2 days by MTT assay Antiproliferative activity against human SUM159 cells assessed as reduction in cell viability incubated for 2 days by MTT assay	[PMID: 31541872]
U-87MG ATCC	EC₅₀	13.5 μM Compound: TFP	Induction of intracellular Ca2+ level in human U87MG cells by Fura-2 AM dye-based assay Induction of intracellular Ca2+ level in human U87MG cells by Fura-2 AM dye-based assay	[PMID: 29614416]
U-87MG ATCC	IC₅₀	9.9 μM Compound: TFP	Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29614416]

In Vitro

Trifluoperazine is a long-established, widely used 'conventional' antipsychotic agent. Trifluoperazine has been an extensively studied drug molecule that has been used as a calmodulin inhibitor^[3]^[4].
Trifluoperazine acts as a reversible inhibitor of influenza virus morphogenesis, but not budding, by disturbing cellular CaM and/or CaM-dependent functions^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 117-89-5
Appearance Solid
Molecular Weight 407.50
Formel C₂₁H₂₄F₃N₃S
Color Off-white to light yellow
SMILES

FC(C(C=C1N2CCCN3CCN(C)CC3)=CC=C1SC4=C2C=CC=C4)(F)F
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (10)

All

Sort by:

Journal Impact Factor

J Transl Med

Suppression of NUPR1 in fibroblast-like synoviocytes reduces synovial fibrosis via the Smad3 pathway. [Abstract]

2024 Aug 1;22(1):715. PMID: 39090667
Free Radic Biol Med

Zinc ions facilitate metabolic bioenergetic recovery post spinal cord injury by activating microglial mitophagy through the STAT3-FOXO3a-SOD2 pathway. [Abstract]

2025 Feb 1:227:64-79. PMID: 39613048
CNS Neurosci Ther

Psilocin suppresses methamphetamine-induced hyperlocomotion and acquisition of conditioned place preference via D2R-mediated ERK signaling. [Abstract]

2023 Mar;29(3):831-841. PMID: 36627756
Food Biosci

2024 Feb, 57, 103513.
Chem Biol Interact

Trifluoperazine activates AMPK / mTOR / ULK1 signaling pathway to induce mitophagy in osteosarcoma cells. [Abstract]

2024 Apr 1:392:110904. PMID: 38360085
Mol Med Rep

Serum from patients with hypertension promotes endothelial dysfunction to induce trophoblast invasion through the miR‑27b‑3p/ATPase plasma membrane Ca2+ transporting 1 axis. [Abstract]

2021 May;23(5):319. PMID: 33760199
Sci Rep

Estrogen regulates duodenal calcium absorption and improves postmenopausal osteoporosis by the effect of ERβ on PMCA1b. [Abstract]

2025 May 8;15(1):16053. PMID: 40341576
BMC Med Genomics

Integrated multi-omic analysis and experiment reveals the role of endoplasmic reticulum stress in lung adenocarcinoma. [Abstract]

2024 Jan 2;17(1):12. PMID: 38167084
Tohoku J Exp Med

Trifluoperazine Synergistically Potentiates Bortezomib-Induced Anti-Cancer Effect in Multiple Myeloma via Inhibiting P38 MAPK/NUPR1. [Abstract]

2022 Jul 22;257(4):315-326. PMID: 35644544
bioRxiv

2024 June 12.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 125 mg/mL (306.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4540 mL

12.2699 mL

24.5399 mL

5 mM

0.4908 mL

2.4540 mL

4.9080 mL

10 mM

0.2454 mL

1.2270 mL

2.4540 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Huerta-Bahena J, Villalobos-Molina R, García-Sáinz JA. Trifluoperazine and chlorpromazine antagonize alpha 1- but not alpha2- adrenergic effects. Mol Pharmacol. 1983;23(1):67-70. [Content Brief]

[2]. Santofimia-Castaño P, et al. Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis. J Clin Invest. 2019;129(6):2500-2513. Published 2019 Mar 28. [Content Brief]

[3]. Marques LO, Lima MS, Soares BG. Trifluoperazine for schizophrenia. Cochrane Database Syst Rev. 2004;2004(1):CD003545. [Content Brief]

[4]. Howland RH. Trifluoperazine: A Sprightly Old Drug. J Psychosoc Nurs Ment Health Serv. 2016;54(1):20-22. [Content Brief]

[5]. Ochiai H, et al. Influence of trifluoperazine on the late stage of influenza virus infection in MDCK cells. Antiviral Res. 1991;15(2):149-160. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4540 mL	12.2699 mL	24.5399 mL	61.3497 mL
	5 mM	0.4908 mL	2.4540 mL	4.9080 mL	12.2699 mL
	10 mM	0.2454 mL	1.2270 mL	2.4540 mL	6.1350 mL
	15 mM	0.1636 mL	0.8180 mL	1.6360 mL	4.0900 mL
	20 mM	0.1227 mL	0.6135 mL	1.2270 mL	3.0675 mL
	25 mM	0.0982 mL	0.4908 mL	0.9816 mL	2.4540 mL
	30 mM	0.0818 mL	0.4090 mL	0.8180 mL	2.0450 mL
	40 mM	0.0613 mL	0.3067 mL	0.6135 mL	1.5337 mL
	50 mM	0.0491 mL	0.2454 mL	0.4908 mL	1.2270 mL
	60 mM	0.0409 mL	0.2045 mL	0.4090 mL	1.0225 mL
	80 mM	0.0307 mL	0.1534 mL	0.3067 mL	0.7669 mL
	100 mM	0.0245 mL	0.1227 mL	0.2454 mL	0.6135 mL

Keywords

Trifluoperazine

10 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Trifluoperazine

Publications Citing Use of MedChemExpress (MCE) Trifluoperazine

Alle Dopamine Receptor Isoform-spezifische Produkte anzeigen

Alle Adrenergic Receptor Isoform-spezifische Produkte anzeigen

Alle CaMK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (10)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Trifluoperazine Related Classifications

HY-B0532 Related Classifications